Year |
Citation |
Score |
2023 |
Ohtonen S, Giudice L, Jäntti H, Fazaludeen MF, Shakirzyanova A, Gómez-Budia M, Välimäki NN, Niskanen J, Korvenlaita N, Fagerlund I, Koistinaho J, Amiry-Moghaddam M, Savchenko E, Roybon L, Lehtonen Š, et al. Human iPSC-derived microglia carrying the LRRK2-G2019S mutation show a Parkinson's disease related transcriptional profile and function. Scientific Reports. 13: 22118. PMID 38092815 DOI: 10.1038/s41598-023-49294-9 |
0.707 |
|
2023 |
Pomeshchik Y, Klementieva O, Gil J, Martinsson I, Hansen MG, de Vries T, Sancho-Balsells A, Russ K, Savchenko E, Collin A, Vaz AR, Bagnoli S, Nacmias B, Rampon C, Sorbi S, et al. Human iPSC-Derived Hippocampal Spheroids: An Innovative Tool for Stratifying Alzheimer Disease Patient-Specific Cellular Phenotypes and Developing Therapies. Stem Cell Reports. 18: 1244-1245. PMID 37163981 DOI: 10.1016/j.stemcr.2023.04.009 |
0.777 |
|
2022 |
Skauli N, Savchenko E, Ottersen OP, Roybon L, Amiry-Moghaddam M. Canonical Bone Morphogenetic Protein Signaling Regulates Expression of Aquaporin-4 and Its Anchoring Complex in Mouse Astrocytes. Frontiers in Cellular Neuroscience. 16: 878154. PMID 35518645 DOI: 10.3389/fncel.2022.878154 |
0.605 |
|
2022 |
Azevedo C, Teku G, Pomeshchik Y, Reyes JF, Chumarina M, Russ K, Savchenko E, Hammarberg A, Lamas NJ, Collin A, Gouras GK, Klementieva O, Hallbeck M, Taipa R, Vihinen M, et al. Parkinson's disease and multiple system atrophy patient iPSC-derived oligodendrocytes exhibit alpha-synuclein-induced changes in maturation and immune reactive properties. Proceedings of the National Academy of Sciences of the United States of America. 119: e2111405119. PMID 35294277 DOI: 10.1073/pnas.2111405119 |
0.706 |
|
2021 |
Pomeshchik Y, Klementieva O, Gil J, Martinsson I, Hansen MG, de Vries T, Sancho-Balsells A, Russ K, Savchenko E, Collin A, Vaz AR, Bagnoli S, Nacmias B, Rampon C, Sorbi S, et al. Human iPSC-derived hippocampal spheroids: An innovative tool for stratifying Alzheimer disease patient-specific cellular phenotypes and developing therapies. Stem Cell Reports. 16: 2838. PMID 34758331 DOI: 10.1016/j.stemcr.2021.10.003 |
0.777 |
|
2021 |
Shamadykova DV, Panteleev DY, Kust NN, Savchenko EA, Rybalkina EY, Revishchin AV, Pavlova GV. Neuroinductive properties of mGDNF depend on the producer, E. Coli or human cells. Plos One. 16: e0258289. PMID 34634077 DOI: 10.1371/journal.pone.0258289 |
0.345 |
|
2021 |
Gustavsson N, Savchenko E, Klementieva O, Roybon L. The intracellular milieu of Parkinson's disease patient brain cells modulates alpha-synuclein protein aggregation. Acta Neuropathologica Communications. 9: 153. PMID 34530929 DOI: 10.1186/s40478-021-01256-w |
0.72 |
|
2021 |
Russ K, Teku G, Bousset L, Redeker V, Piel S, Savchenko E, Pomeshchik Y, Savistchenko J, Stummann TC, Azevedo C, Collin A, Goldwurm S, Fog K, Elmer E, Vihinen M, et al. TNF-α and α-synuclein fibrils differently regulate human astrocyte immune reactivity and impair mitochondrial respiration. Cell Reports. 34: 108895. PMID 33761362 DOI: 10.1016/j.celrep.2021.108895 |
0.752 |
|
2021 |
Keuters MH, Keksa-Goldsteine V, Dhungana H, Huuskonen MT, Pomeshchik Y, Savchenko E, Korhonen PK, Singh Y, Wojciechowski S, Lehtonen Š, Kanninen KM, Malm T, Sirviö J, Muona A, Koistinaho M, et al. An arylthiazyne derivative is a potent inhibitor of lipid peroxidation and ferroptosis providing neuroprotection in vitro and in vivo. Scientific Reports. 11: 3518. PMID 33568697 DOI: 10.1038/s41598-021-81741-3 |
0.715 |
|
2020 |
Pomeshchik Y, Klementieva O, Gil J, Martinsson I, Hansen MG, de Vries T, Sancho-Balsells A, Russ K, Savchenko E, Collin A, Vaz AR, Bagnoli S, Nacmias B, Rampon C, Sorbi S, et al. Human iPSC-Derived Hippocampal Spheroids: An Innovative Tool for Stratifying Alzheimer Disease Patient-Specific Cellular Phenotypes and Developing Therapies. Stem Cell Reports. PMID 32589876 DOI: 10.1016/J.Stemcr.2020.06.001 |
0.761 |
|
2020 |
Azevedo C, Chumarina M, Serafimova E, Goldwurm S, Collin A, Roybon L, Savchenko E, Pomeshchik Y. Generation of an induced pluripotent stem cell line (CSC-32) from a patient with Parkinson's disease carrying a heterozygous variation p.A53T in the SNCA gene. Stem Cell Research. 43: 101694. PMID 31954327 DOI: 10.1016/J.Scr.2019.101694 |
0.777 |
|
2019 |
Savchenko E, Teku GN, Boza-Serrano A, Russ K, Berns M, Deierborg T, Lamas NJ, Wichterle H, Rothstein J, Henderson CE, Vihinen M, Roybon L. FGF family members differentially regulate maturation and proliferation of stem cell-derived astrocytes. Scientific Reports. 9: 9610. PMID 31270389 DOI: 10.1038/S41598-019-46110-1 |
0.766 |
|
2019 |
Korhonen P, Pollari E, Kanninen KM, Savchenko E, Lehtonen Š, Wojciechowski S, Pomeshchik Y, Van Den Bosch L, Goldsteins G, Koistinaho J, Malm T. Long-term interleukin-33 treatment delays disease onset and alleviates astrocytic activation in a transgenic mouse model of amyotrophic lateral sclerosis. Ibro Reports. 6: 74-86. PMID 30705990 DOI: 10.1016/J.Ibror.2019.01.005 |
0.708 |
|
2018 |
Gustavsson N, Marote A, Pomeshchik Y, Russ K, Azevedo C, Chumarina M, Goldwurm S, Collin A, Pinto L, Salgado AJ, Klementieva O, Roybon L, Savchenko E. Generation of an induced pluripotent stem cell line (CSC-46) from a patient with Parkinson's disease carrying a novel p.R301C mutation in the GBA gene. Stem Cell Research. 34: 101373. PMID 30640063 DOI: 10.1016/J.Scr.2018.101373 |
0.742 |
|
2018 |
Savchenko E, Marote A, Russ K, Collin A, Goldwurm S, Roybon L, Pomeshchik Y. Generation of a human induced pluripotent stem cell line (CSC-42) from a patient with sporadic form of Parkinson's disease. Stem Cell Research. 27: 78-81. PMID 29334629 DOI: 10.1016/J.Scr.2018.01.002 |
0.812 |
|
2018 |
Russ K, Marote A, Savchenko E, Collin A, Goldwurm S, Pomeshchik Y, Roybon L. Generation of a human induced pluripotent stem cell line (CSC-40) from a Parkinson's disease patient with a PINK1 p.Q456X mutation. Stem Cell Research. 27: 61-64. PMID 29331938 DOI: 10.1016/J.Scr.2018.01.001 |
0.817 |
|
2015 |
Pomeshchik Y, Kidin I, Korhonen P, Savchenko E, Jaronen M, Lehtonen S, Wojciechowski S, Kanninen K, Koistinaho J, Malm T. Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. Brain, Behavior, and Immunity. 44: 68-81. PMID 25153903 DOI: 10.1016/J.Bbi.2014.08.002 |
0.68 |
|
2014 |
Kärkkäinen V, Pomeshchik Y, Savchenko E, Dhungana H, Kurronen A, Lehtonen S, Naumenko N, Tavi P, Levonen AL, Yamamoto M, Malm T, Magga J, Kanninen KM, Koistinaho J. Nrf2 regulates neurogenesis and protects neural progenitor cells against Aβ toxicity. Stem Cells (Dayton, Ohio). 32: 1904-16. PMID 24753106 DOI: 10.1002/Stem.1666 |
0.729 |
|
2014 |
Pomeshchik Y, Kidin I, Savchenko E, Rolova T, Yamamoto M, Levonen AL, Ylä-Herttuala S, Malm T, Kanninen K, Koistinaho J. Does Nrf2 gene transfer facilitate recovery after contusion spinal cord injury? Antioxidants & Redox Signaling. 20: 1313-23. PMID 23841575 DOI: 10.1089/ars.2013.5453 |
0.702 |
|
Show low-probability matches. |